The Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) were designed to encourage more pediatric studies of drugs used for children. The FDA asked the IOM to review aspects of pediatric studies and changes in product labeling that resulted from BPCA and PREA and their predecessor policies, as well as assess the incentives for pediatric studies of biologics and the extent to which biologics have been studied in children. The IOM committee concludes that these policies have helped provide clinicians who care for children with better information about the efficacy, safety, and appropriate prescribing of drugs. The IOM suggests that more can be done to increase knowledge about drugs used by children and thereby improve the clinical care, health, and well-being of the nation's children.
Table of Contents
|2 Children's Growth and Development and Pediatric Drug Studies||43-62|
|3 Policy Framework for BPCA and PREA||63-88|
|4 Ethical Issues in Pediatric Drug Studies||89-110|
|5 Safety and Efficacy Assessments in Studies Conducted Under BPCA and PREA||111-140|
|6 BPCA, PREA, and Drug Studies with Neonates||141-176|
|7 Outcomes of Written Requests, Requirements, Studies, and Labeling Changes||177-206|
|8 Pediatric Studies of Biologics||207-230|
|Appendix A: Study Activities, Methods, and Public Meetings||261-270|
|Appendix B: Dissemination of Information from Pediatric Studies Conducted Under BPCA and PREA||271-284|
|Appendix C: Biologics in Pediatrics||285-320|
|Appendix D: Biologics Studied and Not Studied in Children||321-380|
|Appendix E: Written Requests for Studies of Pediatric Hypertension: Longitudinal Changes in FDA Specifications||381-386|
|Appendix F: Committee and Staff Biographies||387-394|
The National Academies Press and the Transportation Research Board have partnered with Copyright Clearance Center to offer a variety of options for reusing our content. You may request permission to:
For most Academic and Educational uses no royalties will be charged although you are required to obtain a license and comply with the license terms and conditions.
For information on how to request permission to translate our work and for any other rights related query please click here.
For questions about using the Copyright.com service, please contact:
Copyright Clearance Center
22 Rosewood Drive
Danvers, MA 01923
Tel (toll free): 855/239-3415 (select option 1)
Loading stats for Safe and Effective Medicines for Children: Pediatric Studies Conducted Under the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act...